Black Diamond Therapeutics, Inc.
BDTX
Rank in Stocks
#19431
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to... Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Share Price
$1.86
Last synced: 2026-11-09
Market Cap
$106.58M
Change (1 day)
7.20%
Change (1 year)
-59.74%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Black Diamond Therapeutics, Inc. (BDTX)
Category
Healthcare
Operating Margin for Black Diamond Therapeutics, Inc. (BDTX)
Operating Margin as of November 2026 TTM: 0.00%
According to Black Diamond Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 28.39%.
Operating Margin history for Black Diamond Therapeutics, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | 28.39% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Black Diamond Therapeutics, Inc.'s operating margin
What was Black Diamond Therapeutics, Inc.'s operating margin in 2025?
In 2025, Black Diamond Therapeutics, Inc.'s operating margin was 28.39%, compared with 0.00% in 2024.
How has Black Diamond Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Black Diamond Therapeutics, Inc.'s operating margin was highest in 2025 (28.39%) and lowest in 2024 (0.00%).
How does Black Diamond Therapeutics, Inc.'s operating margin compare with similar companies?
Black Diamond Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.